Imago BioSciences, Inc. (IMGO)
| Market Cap | 822.04M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.70M |
| Shares Out | 32.20M |
| EPS (ttm) | -0.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,318 |
| Open | 25.18 |
| Previous Close | 25.31 |
| Day's Range | 24.50 - 25.86 |
| 52-Week Range | 14.99 - 35.68 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 11, 2021 |
About IMGO
Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing internally-discovered novel inhibitors and degraders of LSD1, an enzyme that plays a central role in the production of blood cells in the bone marrow, to improve the quality of life of patients with cancer and bone marrow diseases, in addition to prolonging their lives. Our lead product candidate is bomedemstat for the treatment of certain myeloproliferative neoplasms, or MPNs, a family of related, chronic cancers of the bone marrow. The three most common...
Financial Performance
Financial StatementsNews
Imago BioSciences Announces Its Addition to the Russell 2000® Index
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO--Imago BioSciences Announces Its Addition to the Russell 2000® Index
Imago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferati...
Imago BioSciences Receives Orphan Designation From European Medicines Agency for Bomedemstat for the Treatment of Ess...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #EMA--Imago BioSciences Receives Orphan Designation from European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia
Imago BioSciences, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Imago BioSciences, Inc. (“Imago”) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferati...
Imago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public Offering
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #ImagoBioSciences--Imago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public Offering
Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #IMGO--Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock
Imago BioSciences IPO Registration Document (S-1)
Imago BioSciences, Inc. has filed to go public with an IPO on the NASDAQ.